Hostname: page-component-84b7d79bbc-5lx2p Total loading time: 0 Render date: 2024-07-26T20:56:47.541Z Has data issue: false hasContentIssue false
  • English
  • Français

Methodology of OTA's Report on Drug Labeling in Developing Countries

Published online by Cambridge University Press:  10 March 2009

Hellen Gelband ,
Jackie Corrigan  and
Robert McDonough
Hellen Gelband
Affiliation:
U.S. Congress, Office of Technology Assessment
Jackie Corrigan
Affiliation:
U.S. Congress, Office of Technology Assessment
Robert McDonough
Affiliation:
U.S. Congress, Office of Technology Assessment
Get access Rights & Permissions [Opens in a new window]

Abstract

This article discusses the methodology of the OTA Project on Drug Labeling in Developing Countries. This report describes (a) the process of the project; (b) observations from a field visit to Thailand; (c) the development of the multinational pharmaceutical industry; and (d) influences on multinational pharmaceutical companies from their home countries, host countries, international organizations, selfregulation, and public interest groups. The results of the assessment will appear in the final report to Congress.

Type
Special Section: Industry and the Generation of Technology
Information
International Journal of Technology Assessment in Health Care , Volume 9 , Issue 2 , Spring 1993 , pp. 238 - 250
Copyright
Copyright © Cambridge University Press 1993

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Bergsten, C. F., Horst, T., & Moran, T. H.American multinationals and American interests. Washington, DC: The Brookings Institution, 1978.Google Scholar
2.Black, R., Blank, S., & Hanson, E. C.Multinationals in contention: Responses at governmental and international levels. New York: The Conference Board, Inc., 1978.Google Scholar
3.Budashevitz, P.Background paper on Thailand. Washington, DC: Office of Technology Assessment, 1988.Google Scholar
4.BUKO (Federal Congress of Development Action Groups). Hoechst: A cause of illness Biefeld, Germany: BUKO Pharma-Kampagne, 1987.Google Scholar
5.Burstall, M. L., & Senior, I.The community’s pharmaceutical industry. Luxembourg, Belgium: Office for Official Publications of the European Communities, 1985.Google Scholar
6. Drug Export Amendment Act of 1986, Pub. L. No. 99–660.Google Scholar
7. Foreign Corrupt Practices Act of 1987.Google Scholar
8.Gereffi, G.The pharmaceutical industry and dependency in the third world. Princeton, NJ: Princeton University Press, 1983.CrossRefGoogle Scholar
9.Heller, T.Poor health, rich profits. Nottingham: Spokesman Books, 1977.Google Scholar
10.Howorka, W. Dangerous drugs. In International Organization of Consumers Unions (ed.), Consumer action in developing countries. Penang, Malaysia: International Organizatio of Consumers Unions, 1980.Google Scholar
11.Hyman, P. M.Legal overview of FDA authority over imports and exports. Food, Drug & Cosmetic Law Journal, 42, 203–12.Google Scholar
12.International Federation of Pharmaceutical Manufacturers Associations. Code information pack. Zurich, Switzerland: IFPMA, 03 1988.Google Scholar
13.International Federation of Pharmaceutical Manufacturers Associations. IFPMA code of pharmaceutical marketing practices. Zurich, Switzerland: IFPMA.Google Scholar
14.International Federation of Pharmaceutical Manufacturers Associations. The international industry discusses marketing standards. Health Horizons, 1988, 4, 1–4.Google Scholar
15.International Federation of Pharmaceutical Manufacturers Associations. Legal and practical requirements for the registration of drugs (medicinal products) for human use. Zurich Switzerland: IFPMA, 1987.Google Scholar
16.Lall, S.The international pharmaceutical industry and less developed countries. Oxford Bulletin of Economics and Statistics, 1974, 36 (August), 143–72.CrossRefGoogle Scholar
17.Ledogar, R. J.Hungry for profits. New York: IDOC/North America, 1975.Google Scholar
18.Pharmaceutical Manufacturers Association. Statistical factbook. Washington, DC: PMA, 12 1987.Google Scholar
19.Redwood, H.The pharmaceutical industry: Trends, problems and achievements. Suffolk, U.K.: Olwicka Press Limited, 1987.Google Scholar
20.SCRIP. Far East pharmaceutical markets: Risks and opportunities. Richmond, U.K.: PJB Publications, 1988.Google Scholar
21.SCRIP. Scrip World Pharmaceutical News. 12 28, 1987, No. 1269.Google Scholar
22.SCRIP. Scrip World Pharmaceutical News. 01 6, 1988, No. 1271.Google Scholar
23.SCRIP. Scrip World Pharmaceutical News. 03 18, 1988, No. 1292.Google Scholar
24.SCRIP. Scrip World Pharmaceutical News. 05 25, 1988, No. 1311.Google Scholar
25.SCRIP. Scrip World Pharmaceutical News. 05 27, 1988, No. 1312.Google Scholar
26.Silverman, M.The drugging of the Americas. Berkeley, CA: University of California Press, 1976.CrossRefGoogle Scholar
27.Silverman, M., & Lee, P. R.Pills, profits & politics. Berkeley, CA: University of California Press, 1974.CrossRefGoogle Scholar
28.Silverman, H., Lee, P. R., & Lydecker, M.Prescriptions for death: The drugging of the third world. Berkeley, CA: University of California Press, 1982.CrossRefGoogle Scholar
29. Thai Drug Act (No. 3) of 1979.Google Scholar
30.United Nations, World Health Organization, Action Programme on Essential Drugs and Vaccines. Summary of progress in the WHO Action Programme on Essential Drugs and Vaccines. Geneva, Switzerland: WHO, 04 1987.Google Scholar
31.United Nations, World Health Organization. Ethical criteria for medicinal drug promo tion. Zurich, Switzerland: WHO, 1988.Google Scholar
32.United Nations, World Health Organization. Review of the drug programme in Thailand: Report of a WHO mission 24 November-12 December 1986. Geneva, Switzerland: World Health Organization, 1988.Google Scholar
33.United Nations, World Health Organization. The use of essential drugs: Third report of the WHO expert committee. Technical Report Series No. 770. Geneva, Switzerland: WHO, 1988.Google Scholar
34.United Nations Centre on Transnational Corporations. Transnational corporations in the pharmaceutical industry of developing countries. New York: United Nations, 1984.Google Scholar
35.U.S. Congress, Congressional Research Service. U.S. direct foreign investment policy: Response to foreign government investment barriers and distortions. Washington, DC: U.S. Government Printing Office, 01 8, 1982.Google Scholar
36.U.S. Congress, Office of Technology Assessment. U.S. drug labeling in developing and newly- industrialized countries: Phase I. Washington, DC: U.S. Government Printing Office, 12 1988.Google Scholar
37.World Bank. World development report. Washington, DC: Oxford University Press, 1989.Google Scholar
38.Yudkin, Y. S.Provision of medicines in a developing country. Lancet, 1978, i, 810.CrossRefGoogle Scholar